Free Trial

Altimmune (ALT) Stock Forecast & Price Target

Altimmune logo
$3.74 +0.03 (+0.67%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Altimmune - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
1
Buy
5

Based on 7 Wall Street analysts who have issued ratings for Altimmune in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, and 5 have given a buy rating for ALT.

Consensus Price Target

$17.40
365.86% Upside
According to the 7 analysts' twelve-month price targets for Altimmune, the average price target is $17.40. The highest price target for ALT is $24.00, while the lowest price target for ALT is $12.00. The average price target represents a forecasted upside of 365.86% from the current price of $3.74.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Altimmune and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALT Analyst Ratings Over Time

TypeCurrent Forecast
9/9/24 to 9/9/25
1 Month Ago
8/10/24 to 8/10/25
3 Months Ago
6/11/24 to 6/11/25
1 Year Ago
9/10/23 to 9/9/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.40$18.20$20.20$18.80
Forecasted Upside365.86% Upside427.54% Upside208.87% Upside194.67% Upside
Consensus RatingModerate BuyModerate BuyBuyModerate Buy

ALT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Altimmune Stock vs. The Competition

TypeAltimmuneMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside369.00% Upside17,269.59% Upside10.52% Upside
News Sentiment Rating
Neutral News

See Recent ALT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/13/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Patrick Trucchio
Patrick Trucchio
1 of 5 stars
Reiterated RatingBuy$12.00+212.09%
8/13/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Eliana Merle
Not Rated
Lower TargetBuy$26.00 ➝ $24.00+524.19%
8/13/2025B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Mayank Mamtani
2 of 5 stars
Lower TargetBuy$20.00 ➝ $18.00+397.24%
7/10/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
7/10/2025JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetMarket Outperform$25.00 ➝ $15.00+256.72%
6/27/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
1/8/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$18.00+146.24%
8/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$25.00 ➝ $25.00+275.94%
4/29/2024Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:31 AM ET.


ALT Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Altimmune is $17.40, with a high forecast of $24.00 and a low forecast of $12.00.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There is currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALT shares.

According to analysts, Altimmune's stock has a predicted upside of 365.86% based on their 12-month stock forecasts.

Over the previous 90 days, Altimmune's stock had 1 upgrade by analysts.

Altimmune has been rated by research analysts at B. Riley, HC Wainwright, JMP Securities, The Goldman Sachs Group, UBS Group, and William Blair in the past 90 days.

Analysts like Altimmune less than other "medical" companies. The consensus rating score for Altimmune is 2.57 while the average consensus rating score for "medical" companies is 2.78. Learn more on how ALT compares to other companies.


This page (NASDAQ:ALT) was last updated on 9/9/2025 by MarketBeat.com Staff
From Our Partners